PO277
20th EADV Congress
Lisbon, Portugal – October 2011
Systemic lupus erythematosus
induced by Infliximab
Rachel L Grynszpan, Ana Paula Frade, Luna Azulay Abulafia,
Washington Bianchi, Danielle de Paula Aguiar, Sueli Carneiro
Sector of Dermatology-HUCFF and
Graduation and Post-Graduation Course,
School of Medicine,
Federal University of Rio de Janeiro - UFRJ, Brazil
Introduction and Objectives
Drug-induced systemic lupus erythematosus is a rare complication and its symptoms
gradually abate after discontinuation of the inducing agent. Rarely involves the kidney
and the CNS. We describe the case of a 22 year-old woman that showed a cutaneous
rash after 2-year use of infliximabe.
Materials and Methods
A 22-year-old woman with rheumatoid arthritis was using infliximabe for 2 years,
methotrexate and corticosteroids and presented cutaneous rash in malar that got
worse after sun exposure. The histopathological findings were suggestive of lupus.
The laboratory findings were: FAN 1/5120 and VHS 156. The lupus diagnostic was
done and the infliximabe was suspended. The treatment for skin lesion was topic
corticosteroids and sunprotection.
Results
 After 1 year using Rituximabe, Methotrexate and corticosteroids, the patient presented
FAN (1/640) decrease, anti-DNAds (1/20) e Anti-histona (7.4) positives, low complement
and negative Anti-SM.
 The skin lesions improved: Drug-induced systemic lupus erythematosus doesn’t have
low complement except when is induced by anti- TNF, anti- ds DNA was not found
except when is induced by anti -TNF and alfa-interferon.
Conclusions
Concluding, we’ve closed the diagnostic Drug-induced systemic lupus erythematosus,
because there was a successful improvement with the suspension of the medication.
Therefore, we believe that the drug has worked as a trigger for the development of the
disease.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Borba et al. Consenso de Lúpus Eritematoso Sistêmico. Temas de Reumatologia Clínica 2009;10(1).
Golmia e Scheinberg. Uso do infliximabe e aparecimento seqüencial de autoanticorpos e neoplasia em paciente com espondiloartrite. Rev Bras Reumatol
2010;50(6):723-28
Grossman L, Barland P. Histone reactivity of drug-induced antinuclear antibodies. A comparison of symptomatic and asymptomatic patients. Arthritis
Rheum 1981;24:927-31.
Katz U et al. Drug-induced lupus: an update. Autoimmun Rev 2010.
Levine D et al. Cutaneous Lupus Erythematosus and Anti-TNF-alfa therapy: A Case Report with Review of the literature. Journal of Drug in Dermatology
2010;9(10).
Martins e Andrade. Formação de auto-anticorpos após terapia anti-TNF-a. Sinopse de Reumatologia 2011;1:5-7.
Mota LMH et al. Lúpus Induzido por Drogas – Da Imunologia Básica à Aplicada. Artigo de Revisão. Rev Bras Reumatol 2007;47(6):431-7.
Moustou AE et al. Cutaneous side effects of antietumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol 2009;61(3).
Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A: Drug-induced lupus erythematosus. Autoimmunity 2005;38(7):507-18.
Srivastava M et al. Drug-induced, Ro/SSA positive cutaneous lupus erythematosus. Arch Dermatol 2003;139:45-9.
Subramanian S et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF
agent. Inflamm Bowel Dis 2011;17.
Vasoo S. Drug-induced lupus: an update. Lupus 2006;15(11):757-61.
Wetter DA et al. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo
Clin Proc 2009.
Zhu LJ et al. Anti-TNF-alpha therapies in systemic lupus erythematosus. in J Biomed Biotechnol 2010.